Drug intelligence / Profile preview

nisotirostide

Development stage: Phase 2
Lead developer: Eli Lilly
Modality: Peptides
Administration: Subcutaneous

Overview

Nisotirostide (LY3457263) is a synthetic peptide drug developed by Eli Lilly and Company for the treatment of metabolic diseases, specifically type 2 diabetes mellitus and obesity. It is administered subcutaneously. Nisotirostide acts as an agonist of neuropeptide Y receptor, which is involved in regulating appetite and energy balance. The drug is classified as an antihyperglycemic agent and represents a new molecular entity in this therapeutic area. Clinical trials have evaluated its safety, tolerability, pharmacokinetics, and efficacy in reducing hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes[1][2][3][4][5].

Other names: nisotirostide

Targets

NPYR (Neuropeptide Y receptors)

Beyond the preview

Go deeper on nisotirostide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nisotirostide.

Explore the full profile